Pharmacogenetic aspect of intravitreal ranibizumab treatment in neovascular age-related macular degeneration: a five-year follow-up

Basit Öğe Kaydı
dc.authoridErdal Yüzbaşıoğlu / 0000-0003-2994-1077en_US
dc.authorscopusidVeysel Sabri Hançer / 6506533543
dc.authorwosidVeysel Sabri Hançer / X-8971-2018
dc.contributor.authorŞengül, Elvan Alper
dc.contributor.authorArtunay, Özgür
dc.contributor.authorRasier, Rıfat
dc.contributor.authorKoçkar, Alev
dc.contributor.authorAfacan, Ceyda
dc.contributor.authorHançer, Veysel Sabri
dc.contributor.authorYuzbaşıoğlu, Erdal
dc.date.accessioned2020-08-30T20:07:51Z
dc.date.available2020-08-30T20:07:51Z
dc.date.issued2018
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose: This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD).Methods: In this retrospective study, 90 nAMD patients' 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years by using pro re nata method.Results: Average visual acuity (BCVA) values in TT group for the third, fourth and fifth years were found to be significantly higher than those in TC and CC groups, while average BCVA values in TC group were significantly higher than those in CC group (all p = .000 < .0167).Conclusion: Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.en_US
dc.identifier.citationSengul, E. A., Artunay, O., Rasier, R., Kockar, A., Afacan, C., Hancer, V. S., & Yuzbasioglu, E. (2018). Pharmacogenetic aspect of intravitreal ranibizumab treatment in neovascular age-related macular degeneration: a five-year follow-up. Ocular immunology and inflammation, 26(6), 971-977.en_US
dc.identifier.doi10.1080/09273948.2017.1311925en_US
dc.identifier.endpage977en_US
dc.identifier.issn0927-3948en_US
dc.identifier.issn1744-5078en_US
dc.identifier.issue6en_US
dc.identifier.pmid28471284en_US
dc.identifier.scopus2-s2.0-85018331077en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage971en_US
dc.identifier.urihttps://doi.org/10.1080/09273948.2017.1311925
dc.identifier.urihttps://hdl.handle.net/20.500.12713/842
dc.identifier.volume26en_US
dc.identifier.wosWOS:000440751300024en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorHançer, Veysel Sabrien_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofOcular Immunology and Inflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAge-Related Macular Degenerationen_US
dc.subjectComplement Factor H Polymorphismen_US
dc.subjectGeneticsen_US
dc.subjectInflammationen_US
dc.subjectIntravitreal Ranibizumaben_US
dc.titlePharmacogenetic aspect of intravitreal ranibizumab treatment in neovascular age-related macular degeneration: a five-year follow-upen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
229.pdf
Boyut:
487.03 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu